Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ClinicalTrials.gov ID: NCT07284979

Public ClinicalTrials.gov record NCT07284979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Study identification

NCT ID: NCT07284979
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Kailera; Industry
Enrollment: 1,200 participants

Conditions and interventions

Conditions

Obesity

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 29, 2025
Primary completion: Feb 29, 2028
Completion: Mar 31, 2028
Last update posted: Aug 31, 2026

2025 – 2028

United States locations

U.S. sites: 27
U.S. states: 19
U.S. cities: 27

Facility	City	State	ZIP	Site status
Kailera Clinical Site	Glendale	Arizona	85308	Recruiting
Kailera Clinical Site	Phoenix	Arizona	85012	Recruiting
Kailera Clinical Site	Little Rock	Arkansas	72205	Recruiting
Kailera Clinical Site	Northridge	California	91325	Recruiting
Kailera Clinical Site	Oceanside	California	92058	Recruiting
Kailera Clinical Site	Hamden	Connecticut	06517	Recruiting
Kailera Clinical Site	Stamford	Connecticut	06905	Recruiting
Kailera Clinical Site	Orange City	Florida	32763	Recruiting
Kailera Clinical Site	Albany	Georgia	31707	Recruiting
Kailera Clinical Site	Chicago	Illinois	60640	Recruiting
Kailera Clinical Site	Skokie	Illinois	60077	Recruiting
Kailera Clinical Site	Newton	Kansas	67114	Recruiting
Kailera Clinical Site	Shreveport	Louisiana	71105	Recruiting
Kailera Clinical Site	Farmington Hills	Michigan	48334	Recruiting
Kailera Clinical Site	Missoula	Montana	59804	Recruiting
Kailera Clinical Site	Las Vegas	Nevada	89148	Recruiting
Kailera Clinical Site	Albany	New York	12203	Recruiting
Kailera Clinical Site	Morehead City	North Carolina	28557	Recruiting
Kailera Clinical Site	Morrisville	North Carolina	27560	Recruiting
Kailera Clinical Site	Norman	Oklahoma	73069	Recruiting
Kailera Clinical Site	East Greenwich	Rhode Island	02818	Recruiting
Kailera Clinical Site	North Charleston	South Carolina	29405	Recruiting
Kailera Clinical Site	Spartanburg	South Carolina	29303	Recruiting
Kailera Clinical Site	Brownsville	Texas	78526	Recruiting
Kailera Clinical Site	San Antonio	Texas	78229	Recruiting
Kailera Clinical Site	Manassas	Virginia	20110	Recruiting
Kailera Clinical Site	Richmond	Virginia	23236	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07284979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07284979 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →